UNSPSC 51382402: Diflumidone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11F2NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E96467495S chemically known as 3'-benzoyl-1,1-difluoromethanesulfonanilide but generally known as diflumidone, which bears US NIH Compound Identifier 31501. European Medicines Agency schedules Diflumidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07129MIG.

UNSPSC 51382402 Diflumidone is a Commodity code that describes a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code involves broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and drug deactivation systems — rather than diflumidone itself. State and local issuing bodies soliciting under pharmaceutical-related codes include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work spans product sourcing, compliance with cGMP and Drug Supply Chain Security Act requirements, pricing negotiation, wholesaler coordination, and delivery logistics to public health facilities and community health buildings.

Recent opportunities show activity across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: due date predates posting date in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must maintain authorized wholesaler relationships, comply with FDA requirements and DSCSA, carry specific insurance thresholds, and accept performance penalties for reporting or fulfillment failures.